Thus, future studies combining prospective clinical trials and experimental animal models are needed to further establish S100A6 measurements in the diagnosis of cholangiocarcinoma and to define the exact role of S100 family members in the pathophysiology of this devastating disease. This evidence concerns the gene S100A6 and cholangiocarcinoma.